🔄 Hydroxychloroquine Cancer Research

Hydroxychloroquine, traditionally known as an antimalarial medication, has emerged as a subject of significant interest in cancer research. Scientists are investigating how this drug may interrupt autophagy—a cellular process where cancer cells essentially recycle themselves to survive and proliferate. By potentially inhibiting autophagy, hydroxychloroquine could starve cancer cells of this critical survival mechanism, making it a promising candidate for off-label cancer treatment studies.

The research into hydroxychloroquine's anticancer potential represents an important example of drug repurposing in oncology. Rather than developing entirely new compounds, researchers are examining existing medications with established safety profiles to identify new therapeutic applications. This approach can accelerate the translation of scientific discoveries into clinical practice while potentially offering patients additional treatment options. Multiple clinical trials and laboratory studies are currently exploring hydroxychloroquine alone and in combination with conventional chemotherapy or targeted therapies across various cancer types.

On this page, you'll find the latest peer-reviewed research on hydroxychloroquine in cancer treatment. Our curated collection includes clinical trial results, mechanistic studies, and expert analysis to help patients, caregivers, and healthcare providers understand the current state of this research. While early findings are encouraging, it's important to note that hydroxychloroquine remains under investigation for cancer applications, and any use should only occur under direct medical supervision.